Success Metrics

Completion Rate
0%(0/3)
Active Trials
0(0%)
Terminated
3(75%)

Phase Distribution

Ph phase_3
1
25%
Ph phase_2
3
75%

Phase Distribution

0

Early Stage

3

Mid Stage

1

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
3(75.0%)
Phase 3Large-scale testing
1(25.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 3 finished

Non-Completion Rate

100.0%

3 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Terminated(3)
Other(1)

Detailed Status

Terminated3
Suspended1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
0.0%
Most Advanced
Phase 3

Trials by Phase

Phase 23 (75.0%)
Phase 31 (25.0%)

Trials by Status

terminated375%
suspended125%

Recent Activity

0 active trials
Showing 4 of 4
terminatedphase_2

Evaluating the Early Bactericidal Activity, Safety and Tolerability of Nebulised RESP301 in Adults With Tuberculosis

NCT06041919
suspendedphase_3

Preventing Pulmonary Complications in Surgical Patients at Risk of COVID-19

NCT04386070
terminatedphase_2

COmmunity Patients at Risk of Viral Infections Including SARS-CoV-2

NCT04858451
terminatedphase_2

Study of a Nebulised Nitric Oxide Generating Solution in Patients With Mycobacterium Abscessus

NCT05101915

Clinical Trials (4)

Showing 4 of 4 trials
NCT06041919Phase 2

Evaluating the Early Bactericidal Activity, Safety and Tolerability of Nebulised RESP301 in Adults With Tuberculosis

Terminated
NCT04386070Phase 3

Preventing Pulmonary Complications in Surgical Patients at Risk of COVID-19

Suspended
NCT04858451Phase 2

COmmunity Patients at Risk of Viral Infections Including SARS-CoV-2

Terminated
NCT05101915Phase 2

Study of a Nebulised Nitric Oxide Generating Solution in Patients With Mycobacterium Abscessus

Terminated

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4